{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:52:38Z","timestamp":1792497158417,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12072-024-10752-9","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T10:16:51Z","timestamp":1732702611000},"page":"395-404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study"],"prefix":"10.1007","volume":"19","author":[{"given":"Chia-Chih","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hsiang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hsien","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Tao","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"8","key":"10752_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2459\/JCM.0000000000001646","volume":"25","author":"M Yu","year":"2024","unstructured":"Yu M, Zhao S, Fan X, Lv Y, Xiang L, Li R. Sodium\u2013glucose cotransporter-2 inhibitors and abnormal serum potassium: a real-world, pharmacovigilance study. J Cardiovasc Med (Hagerstown). 2024;25(8):613\u2013622","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10752_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.08.020","author":"M Zamani","year":"2024","unstructured":"Zamani M, Alizadeh-Tabari S, Ajmera V, Singh S, Murad MH, Loomba R. Global prevalence of advanced liver fibrosis and cirrhosis in the general population: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.cgh.2024.08.020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10752_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999-2010.e8","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10752_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234","journal-title":"Signal Transduct Target Ther"},{"key":"10752_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47:187\u20131888","journal-title":"Diabetes Care"},{"issue":"14","key":"10752_CR6","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.7150\/thno.86831","volume":"13","author":"P Ghosh","year":"2023","unstructured":"Ghosh P, Fontanella RA, Scisciola L, Pesapane A, Taktaz F, Franzese M, et al. Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists. Theranostics. 2023;13(14):4872\u20134884","journal-title":"Theranostics"},{"issue":"10","key":"10752_CR7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","volume":"9","author":"RJ Jalleh","year":"2024","unstructured":"Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol. 2024;9(10):957\u2013964","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10752_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.07.012","author":"A Morissette","year":"2024","unstructured":"Morissette A, Mulvihill EE. Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist-based therapies. Trends Endocrinol Metab. 2024. https:\/\/doi.org\/10.1016\/j.tem.2024.07.012","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"10752_CR9","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1016\/j.apsb.2022.06.003","volume":"12","author":"J Pang","year":"2022","unstructured":"Pang J, Feng JN, Ling W, Jin T. The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-therapeutic potential exploration in lung injury. Acta Pharm Sin B. 2022;12(11):4040\u20134055","journal-title":"Acta Pharm Sin B"},{"key":"10752_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108270","volume":"239","author":"S Shao","year":"2022","unstructured":"Shao S, Zhang X, Xu Q, Pan R, Chen Y. Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities. Pharmacol Ther. 2022;239: 108270","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10752_CR11","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.metabol.2016.04.004","volume":"65","author":"D Barb","year":"2016","unstructured":"Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1183\u20131195","journal-title":"Metabolism"},{"issue":"23","key":"10752_CR12","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1001\/jama.2024.7112","volume":"331","author":"JM Lee","year":"2024","unstructured":"Lee JM, Sharifi M, Oshman L, Griauzde DH, Chua KP. Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020\u20132023. JAMA. 2024;331(23):2041\u20132043","journal-title":"JAMA"},{"key":"10752_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol Metab. 2021;46: 101102","journal-title":"Mol Metab"},{"issue":"12","key":"10752_CR14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u20131124","journal-title":"N Engl J Med"},{"key":"10752_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15898","author":"T Arai","year":"2024","unstructured":"Arai T, Atsukawa M, Tsubota A, Oikawa T, Tada T, Matsuura K, et al. Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: a prospective, multicentre, observational study. Diabet Obes Metab. 2024. https:\/\/doi.org\/10.1111\/dom.15898","journal-title":"Diabet Obes Metab"},{"issue":"2","key":"10752_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, London JW, Perez-Rey D, Drebert ZJ, Winer-Jones JP, Thompson CN, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6(2):35","journal-title":"JAMIA Open"},{"key":"10752_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332687","author":"S Bea","year":"2024","unstructured":"Bea S, Ko HY, Bae JH, Cho YM, Chang Y, Ryu S, et al. Risk of hepatic events associated with use of sodium\u2013glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2024. https:\/\/doi.org\/10.1136\/gutjnl-2024-332687","journal-title":"Gut"},{"issue":"4","key":"10752_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","volume":"167","author":"L Wang","year":"2024","unstructured":"Wang L, Berger NA, Kaelber DC, Xu R. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology. 2024;167(4):689\u2013703","journal-title":"Gastroenterology"},{"issue":"10","key":"10752_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102849","volume":"17","author":"S Bandyopadhyay","year":"2023","unstructured":"Bandyopadhyay S, Das S, Samajdar SS, Joshi SR. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17(10): 102849","journal-title":"Diabetes Metab Syndr"},{"issue":"8","key":"10752_CR20","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/imj.16126","volume":"53","author":"B Stretton","year":"2023","unstructured":"Stretton B, Kovoor J, Bacchi S, Chang S, Ngoi B, Murray T, et al. Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review. Intern Med J. 2023;53(8):1311\u20131320","journal-title":"Intern Med J"},{"key":"10752_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10752_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00125-023-06057-5","volume":"67","author":"A Krishnan","year":"2024","unstructured":"Krishnan A, Schneider CV, Hadi Y, Mukherjee D, AlShehri B, Alqahtani SA. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study. Diabetologia. 2024;67(3):483\u2013493","journal-title":"Diabetologia"},{"key":"10752_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16132","author":"Z Rashid","year":"2024","unstructured":"Rashid Z, Woldesenbet S, Khalil M, Iyer S, Khan MMM, Altaf A, et al. Impact of GLP-1RA on the risk of adverse liver outcomes among patients with alcohol-associated liver disease and type 2 diabetes. Liver Int. 2024. https:\/\/doi.org\/10.1111\/liv.16132","journal-title":"Liver Int"},{"issue":"3","key":"10752_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/joim.13751","volume":"295","author":"CT Yang","year":"2024","unstructured":"Yang CT, Yao WY, Yang CY, Peng ZY, Ou HT, Kuo S. Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: a nationwide cohort study using target trial emulation framework. J Intern Med. 2024;295(3):357\u2013368","journal-title":"J Intern Med"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10752-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10752-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10752-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:36:16Z","timestamp":1744781776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10752-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10752"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10752-9","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Institutional Review Board of the Chi Mei Medical Center approved the study protocol. Written informed consent was not required because TriNetX contains anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to the publishing of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}